^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Skyclarys (omaveloxolone)

i
Other names: RTA 408, RTA-408, ABT-RTA-408, RTA408
Associations
Company:
Biogen
Drug class:
NRF2 activator
Associations
20d
Enrollment open
|
Skyclarys (omaveloxolone)
1m
SKYCLARYS® (Omaveloxolone) Pregnancy and Lactation Surveillance Program (clinicaltrials.gov)
P=N/A, N=20, Recruiting, Reata, a wholly owned subsidiary of Biogen | Not yet recruiting --> Recruiting
Enrollment open • Adverse events
|
Skyclarys (omaveloxolone)
2ms
SKYCLARYS® (Omaveloxolone) Pregnancy and Lactation Surveillance Program (clinicaltrials.gov)
P=N/A, N=20, Not yet recruiting, Reata, a wholly owned subsidiary of Biogen
New trial • Adverse events
|
Skyclarys (omaveloxolone)
2ms
New trial
|
Skyclarys (omaveloxolone)
2ms
New P1 trial
|
Skyclarys (omaveloxolone)
5ms
A Study of Omaveloxolone in Children With Friedreich's Ataxia (clinicaltrials.gov)
P1, N=20, Recruiting, Reata, a wholly owned subsidiary of Biogen | Not yet recruiting --> Recruiting
Enrollment open
|
Skyclarys (omaveloxolone)
5ms
A Study of Omaveloxolone in Children With Friedreich's Ataxia (clinicaltrials.gov)
P1, N=20, Not yet recruiting, Reata, a wholly owned subsidiary of Biogen | Trial completion date: Feb 2024 --> Feb 2030 | Initiation date: Nov 2023 --> Jul 2024 | Trial primary completion date: Feb 2024 --> Feb 2030
Trial completion date • Trial initiation date • Trial primary completion date
|
Skyclarys (omaveloxolone)
9ms
RTA 408 Capsules in Patients With Melanoma - REVEAL (clinicaltrials.gov)
P1/2, N=41, Completed, Reata, a wholly owned subsidiary of Biogen | Phase classification: P1b/2 --> P1/2
Phase classification • Combination therapy • Metastases
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Skyclarys (omaveloxolone)
over1year
Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer. (PubMed, J Cancer Res Clin Oncol)
This discovery revealed the specific mechanism of ferroptosis induced by apatinib combined with olaparib in p53 wild-type ovarian cancer cells and provided a theoretical basis for the clinical combined use of apatinib and olaparib in p53 wild-type ovarian cancer patients.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA (Breast cancer early onset) • GPX4 (Glutathione Peroxidase 4)
|
TP53 mutation • TP53 wild-type • BRCA wild-type • GPX4 expression
|
Lynparza (olaparib) • AiTan (rivoceranib) • sirolimus • RITA • Skyclarys (omaveloxolone)
over2years
In Vitro Efficacy and Molecular Mechanism of Curcumin Analog in Pathological Regulation of Spinocerebellar Ataxia Type 3. (PubMed, Antioxidants (Basel))
Unlike other nuclear factor erythroid-2-related factor 2 (Nrf2) activators, the mechanism of action of curcumin analog, ASC-JM17 (JM17), in regulating oxidative homeostasis remains unknown...Presently, we compared actions of JM17 with those of known Nrf2 activators, omaveloxolone (RTA-408) and dimethyl fumarate (DMF), using human neuroblastoma SK-N-SH cells with stable transfection of full-length ataxin-3 protein with 78 CAG repeats (MJD78) to clarify the resulting pathological mechanism by assaying mitochondrial function, mutant ataxin-3 protein toxicity, and oxidative stress...It showed that activation of Nrf2 in response to ROS generated in mitochondria could play an import role in the benefit of JM17. This study presents the diversified regulation of JM17 in a pathological process and helped develop more effective therapeutic strategies for SCA3.
Preclinical • Journal
|
ATXN3 (Ataxin 3) • SOD2 (Superoxide Dismutase 2)
|
NFE2L2 mutation
|
Skyclarys (omaveloxolone)
3years
The Effects of Two Nrf2 Activators, Bardoxolone Methyl and Omaveloxolone, on Retinal Ganglion Cell Survival during Ischemic Optic Neuropathy. (PubMed, Antioxidants (Basel))
Our results provide explicit evidence that RTA 402 modulates the Nrf2 and NFκB signaling pathways to protect RGCs from apoptosis and maintain the visual function in an rAION model. These findings indicate that RTA 402 may a potential therapeutic agent for ischemic optic neuropathy.
Journal
|
IL6 (Interleukin 6) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
IL6 expression
|
Skyclarys (omaveloxolone)